Related Experiment Video

Updated: May 12, 2026

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

Denosumab in breast cancer treatment

Jan C Drooger1, Annemieke van der Padt, Stefan Sleijfer

  • 1Erasmus MC Cancer Institute, Department of Medical Oncology, P.O. Box 5201, 3008 AE Rotterdam, The Netherlands.

European Journal of Pharmacology
|April 3, 2013
PubMed

Insights

Denosumab, a targeted bone therapy, significantly delays skeletal events in breast cancer patients with bone metastases. It also improves bone mineral density in those treated with aromatase inhibitors.

Area of Science:

  • Oncology
  • Pharmacology
  • Bone Biology

Background:

  • Bone is the most frequent site of breast cancer metastasis.
  • Denosumab is a monoclonal antibody targeting receptor activator of nuclear factor kappa-B ligand (RANKL).
  • Denosumab represents a novel targeted bone therapy for cancer patients.

Purpose of the Study:

  • To review current denosumab indications in breast cancer treatment.
  • To evaluate denosumab's efficacy, toxicity, and clinical relevance.
  • To propose future research directions for denosumab in oncology.

Main Methods:

  • Review of a large randomized phase III head-to-head study comparing denosumab and zoledronic acid.
  • Analysis of a phase III study on denosumab's effect on bone mineral density in the adjuvant setting.
  • Inclusion of preclinical data on denosumab's impact on tumor growth and carcinogenesis.

Main Results:

  • Denosumab significantly delayed the time to the first skeletal-related event compared to zoledronic acid in patients with bone metastases.
  • Denosumab significantly increased bone mineral density compared to placebo in patients receiving aromatase inhibitors.
  • Preclinical data suggest denosumab may influence tumor growth and carcinogenesis.

Conclusions:

  • Denosumab is effective in managing bone metastases and improving bone health in breast cancer patients.
  • Understanding denosumab's efficacy and toxicity is crucial for clinical practice.
  • Further research is needed to explore denosumab's full potential in breast cancer treatment.
Keywords:
Bone metastasisBreast cancerDenosumab

More Related Videos

Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment10:13

Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment

Published on: June 21, 2022

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...